InsiderTrades

Form 4 for DNLI Denali Therapeutics Inc.

Accepted 2024-10-22 00:00:00 ET · period of report 2024-10-18 · accession 0001714899-24-000206 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2024-10-22 2024-10-18 DNLI Watts Ryan J. Pres, CEO, Dir M - OptEx $0.68 +40.0K 275.8K +17% +$27.2K
D 2024-10-22 2024-10-18 DNLI Watts Ryan J. Pres, CEO, Dir S - Sale+OE $27.69 -40.0K 235.8K -15% -$1.11M
D 2024-10-22 2024-10-18 DNLI Watts Ryan J. Pres, CEO, Dir M - OptEx $0.00 -40.0K 1.08M -4% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-10-18 M A 40,000 $0.68 275,807 D — — (F1) Includes 197,200 Unvested RSUs.
2 Common Common Stock 2024-10-18 S D 40,000 $27.69 235,807 D — — (F3) The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $27.49 to $28.00 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. (F1) Includes 197,200 Unvested RSUs.
3 Derivative Stock Option (right to buy) 2024-10-18 M D 40,000 $0.00 1,078,091 D $0.68 · — to 2025-08-20 40,000 Common Stock (F5) The vesting of the shares subject to the option are contingent upon the achievement of certain performance metrics. 50% of the shares subject to the option vested on March 3, 2021, and 50% of the shares subject to the option will vest on the date the closing price of Issuer's Common Stock equals or exceeds $80.00 per share on NASDAQ for 90 consecutive trading days.